J&J Competition Threat Overblown, AbbVie's Skyrizi Franchise Remains Dominant

What happened

Johnson & Johnson has signaled ambition to compete with AbbVie's key growth driver Skyrizi, but the Motley Fool article argues the threat is manageable and investors should not panic. The DeepValue Master Report already factors in competitive dynamics, with a WAIT rating and a base case that Skyrizi sustains share capture. The article's reassurance aligns with AbbVie's disclosed metrics of strong frontline IBD capture and psoriasis share, suggesting J&J's entry may not materially disrupt near-term growth. However, investors should remain vigilant for any erosion in share metrics, as the thesis relies heavily on Skyrizi and Rinvoq's performance.

Implication

The J&J threat is a known risk already discounted in the WAIT rating. Long-term investors should focus on execution of the 2026 immunology framework and the durability of Rinvoq's exclusivity. Any significant degradation in Skyrizi's market share would warrant reassessment.

Thesis delta

The article reinforces the existing thesis rather than changing it. The baseline assumption of sustained Skyrizi leadership remains intact, but the competitive landscape warrants continued monitoring. No adjustment to the rating or entry/exit points is needed at this time.